View Older Stories View More Recent Stories

Mar 2, 2022 06:45AM Pfizer (PFE) Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV in Infants from Birth up to Six Months of Age by Active Immunizati
Mar 2, 2022 06:45AM Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus (RSV) Vaccine Candidate for the Prevention of RSV in Infants from Birth up to Six Months of Age by Active Immunizati
Mar 1, 2022 06:45AM Pfizer (PFE) Reports Phase 3 CLOVER Trial Results
Mar 1, 2022 06:45AM Phase 3 CLOVER Trial for Pfizer’s Investigational Clostridioides Difficile Vaccine Indicates Strong Potential Effect in Reducing Duration and Severity of Disease Based on Secondary Endpoints
Feb 28, 2022 10:00AM Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Feb 25, 2022 07:00AM Biohaven Pharma (BHVN) Pfizer (PFE) Receive Positive CHMP Opinion for Migraine Treatment
Feb 25, 2022 06:59AM Biohaven and Pfizer Receive Positive CHMP Opinion for Migraine Treatment
Feb 22, 2022 10:00AM Pfizer Invites Public to View and Listen to Webcast of Pfizer Keynote Presentation at Healthcare Conference
Feb 15, 2022 11:09AM Pfizer (PFE), OPKO’s (OPK) Once-Weekly NGENLA Injection Receives Marketing Authorization in European Union for Treatment of Pediatric GHD
Feb 15, 2022 11:08AM Pfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency
Feb 15, 2022 10:04AM EMA Approves Pfizer’s (PFE) 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults
Feb 15, 2022 10:02AM European Medicines Agency Approves Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults
Feb 14, 2022 07:01AM Biohaven Pharma (BHVN), Pfizer (PFE) Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea
Feb 14, 2022 07:00AM Biohaven and Pfizer Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea
Feb 11, 2022 01:32PM Pfizer (PFE)/BioNTech (BNTX) Provide Update on Rolling Submission for EAU for COVID-19 Vaccine for Children
Feb 11, 2022 01:30PM Pfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age
Feb 9, 2022 10:00AM Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Feb 4, 2022 05:27AM Pfizer (PFE) and Valneva (VALN) Report Additional Positive Phase 2 Data for Lyme Disease Vaccine Candidate
Feb 4, 2022 01:00AM Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate
Feb 1, 2022 04:27PM Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request from U.S. FDA
Feb 1, 2022 04:20PM Pfizer (PFE) and BioNTech (BNTX) Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4
Feb 1, 2022 04:20PM Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request From U.S. FDA
Feb 1, 2022 12:15PM Pfizer (PFE) Announces New Chief Development Officer
Feb 1, 2022 12:15PM Pfizer Announces New Chief Development Officer
Jan 31, 2022 07:07AM Pfizer (PFE), Ionis (IONS) announce discontinuation of vupanorsen clinical development program
Jan 31, 2022 07:05AM Pfizer and Ionis announce discontinuation of vupanorsen clinical development program
Jan 28, 2022 09:46AM Pfizer (PFE) Announces European Commission Approves LORVIQUA as First-Line Treatment for ALK-Positive Advanced Lung Cancer
Jan 28, 2022 09:46AM European Commission Approves LORVIQUA® (lorlatinib) as a First-Line Treatment for ALK-Positive Advanced Lung Cancer
Jan 27, 2022 09:11AM Pfizer (PFE) Announces Positive CHMP Opinion for COVID-19 Oral Treatment
Jan 27, 2022 09:11AM Pfizer Receives CHMP Positive Opinion for Novel COVID-19 Oral Treatment
Jan 25, 2022 06:45AM Pfizer (PFE), BioNTech (BNTX) Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults
Jan 25, 2022 06:45AM Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age
Jan 25, 2022 06:45AM  Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age
Jan 24, 2022 09:25AM Pre-Open Stock Movers 01/24: (EXTN) (KSS) (UL) Higher; (OPK) (MSTR) (MARA) Lower (more...)
Jan 21, 2022 04:30PM Pfizer (PFE) and OPKO (OPK) Receive CRL for BLA for Somatrogon for Pediatric Growth Hormone Deficiency
Jan 21, 2022 04:30PM Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency
Jan 20, 2022 08:03AM OPKO Health (OPK) and Pfizer (PFE) Announce Approval of NGENLA in Japan
Jan 20, 2022 08:00AM Japan’s MHLW Approves Pfizer and OPKO’s NGENLA® (Somatrogon), a New Long-Acting Treatment for Pediatric Growth Hormone Deficiency
Jan 14, 2022 03:31PM Pfizer (PFE) Announces U.S. FDA Approves CIBINQO for Adults with Moderate-to-Severe Atopic
Jan 14, 2022 03:30PM U.S. FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis
Jan 12, 2022 06:47AM Pfizer (PFE) Reports Positive Top-Line Results of Phase 3 Study Exploring Coadministration of PREVNAR 20 With Pfizer-BioNTech COVID-19 Vaccine in Older Adults Released
Jan 12, 2022 06:45AM Positive Top-Line Results of Pfizer’s Phase 3 Study Exploring Coadministration of PREVNAR 20™ With Pfizer-BioNTech COVID-19 Vaccine in Older Adults Released
Jan 11, 2022 06:51AM Becton Dickinson (BDX), Pfizer (PFE) and Wellcome Collaborate to Improve Global Hospital Antimicrobial Stewardship Practices
Jan 10, 2022 06:30AM Pfizer (PFE) Enters Pact with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics
Jan 10, 2022 06:30AM Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics
Jan 10, 2022 06:03AM Pfizer (PFE) Enters Exclusive Collaboration with Beam (BEAM) for Novel In Vivo Base Editing Programs for a Range of Rare Diseases
Jan 10, 2022 06:00AM Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases
Jan 10, 2022 06:00AM Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases
Jan 10, 2022 06:00AM Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases
Jan 5, 2022 07:04AM Biohaven Pharma (BHVN), Pfizer (PFE) Complete Collaboration Transaction for Commercialization of Rimegepant and Zavegepant Outside United States
View More Recent Stories View Older Stories